Skip to content

Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970
505.64 +3.33 +0.66%
Live - 5344 symbols - heartbeat 25s ago · 2026-10-08 08:19
Pre-market 506.67 +0.20%
After-hours 505.80 +0.03%
Overnight 505.01 -0.12%
Market cap
128.16B
P/B
6.33
EPS
15.32
Reader sentiment Are you bullish or bearish on VRTX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
    Market Newswire · 2026/9/29
  • Rating change
    UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
    Market Newswire · 2026/8/20
  • Rating change
    Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $665
    Market Newswire · 2026/9/2
  • UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $615
    Market Newswire · 2026/9/28
  • Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $608
    Market Newswire · 2026/9/25
  • Rating change
    Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $665
    Market Newswire · 2026/9/15
  • Rating change
    A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $633
    Market Newswire · 2026/8/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
    TipRanks · 2026/9/2
  • Rating change
    Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
    Market Newswire · 2026/9/2
  • Rating change
    Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $558
    Market Newswire · 2026/9/16
  • A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $672
    Market Newswire · 2026/9/23
  • Rating change
    William Blair Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
    Market Newswire · 2026/8/10
  • Rating change
    Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $500
    Market Newswire · 2026/8/10
  • A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $617
    Market Newswire · 2026/9/24
  • Rating change
    J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $560
    Market Newswire · 2026/9/11
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
    TipRanks · 2026/9/22
  • Rating change
    BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $672
    Market Newswire · 2026/8/11
  • Rating change
    BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
    Market Newswire · 2026/8/18
  • Rating change
    Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
    Market Newswire · 2026/8/6
  • Rating change
    RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $570
    Market Newswire · 2026/8/13
  • News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
    Dow Jones · 9/2
  • Vertex Pharmaceuticals Names Jonathan Poole Chief Financial Officer, Effective Jan. 1 VRTX
    Dow Jones · 9/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:19:31 · For reference only, not investment advice and not tailored to your situation.